Diabetes type 2

Patients with hypertension:  1 trials  - SHEP (diabetic subgroup)

chlorthalidone vs placebo

No demonstrated result

suggested cardiovascular events by 34% (not demonstrated)

See more clinical conditions

Patients with or without hypertension:  1 trials  - SHEP (diabetic subgroup)

chlorthalidone vs placebo

No demonstrated result

suggested cardiovascular events by 34% (not demonstrated)

Hypertension

All type of patient:  3 trials  - VA-NHLBI - SHEP - SHEP-pilot

chlorthalidone vs placebo

No demonstrated result

suggested cardiovascular events by 29% (not demonstrated)

suggested stroke (fatal and non fatal) by 36% (not demonstrated)

suggested Coronary event by 22% (not demonstrated)

suggested Heart failure by 43% (not demonstrated)

See more clinical conditions

Diabetic patients :  1 trials  - SHEP (diabetic subgroup)

chlorthalidone vs placebo

No demonstrated result

suggested cardiovascular events by 34% (not demonstrated)

Uncomplicated hypertension:  3 trials  - VA-NHLBI - SHEP - SHEP-pilot

chlorthalidone vs placebo

No demonstrated result

suggested cardiovascular events by 29% (not demonstrated)

suggested stroke (fatal and non fatal) by 36% (not demonstrated)

suggested Coronary event by 22% (not demonstrated)

suggested Heart failure by 43% (not demonstrated)

Very ederly (80 and more):  2 trials  - SHEP-P (subgroup ) - SHEP (subgroup )

chlorthalidone vs placebo

No demonstrated result

suggested cardiovascular events by 33% (not demonstrated)

suggested stroke (fatal and non fatal) by 51% (not demonstrated)

suggested Heart failure by 62% (not demonstrated)




- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons